Meiji Seika Pharma to buy 7.9% stake in Arcturus Therapeutics for $50 million
ARCT•
ARCT•Meiji Seika Pharma will buy $50 million of Arcturus Therapeutics securities for a 7.9% post-transaction stake at $20.27 per share, an 80% premium. The proceeds will support ARCT-2601 development and the companies are expanding their collaboration.
Meiji Seika Pharma will purchase $50 million of Arcturus Therapeutics’ unregistered securities, giving it a 7.9% post-transaction stake. The $20.27 per-share price represents an 80% premium. Proceeds will accelerate development of ARCT-2601 for OTC deficiency and support clinical validation of the LUNAR 2.0 mRNA delivery platform. The expanded collaboration includes an exclusive license to apply ARCT-154 technology in an undisclosed therapeutic area, while a memorandum of understanding outlines potential pandemic preparedness and response collaboration in Japan.